Back
Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program
Journal article

Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program

  • Filipits, Martin From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Pirker, Robert From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Dunant, Ariane From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Lantuejoul, Sylvie From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Schmid, Katharina From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Huynh, Anh From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Haddad, Vincent From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • André, Fabrice From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Stahel, Rolf From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Pignon, Jean-Pierre From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Soria, Jean-Charles From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Popper, Helmut H. From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Le Chevalier, Thierry From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Brambilla, Elisabeth From the Departments of Medicine I and Clinical Pathology, Medical University of Vienna, Vienna; Institute of Pathology, Medical University of Graz, Graz, Austria; Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif; L'Institut National de la Santé et de la Recherche Médicale U823, Université Joseph Fourier, Department of Pathology, Grenoble Hospital, Grenoble, France; and Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
Show more…
Published in:
  • Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2007, vol. 25, no. 19, p. 2735-2740
Cancer Research
Oncology
English PurposeThe International Adjuvant Lung Cancer Trial (IALT) demonstrated that adjuvant cisplatin-based chemotherapy improves the survival of patients with completely resected non–small-cell lung cancer (NSCLC). The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT.Patients and MethodsExpression of p27Kip1, p16INK4A, cyclin D1, cyclin D3, cyclin E, and Ki-67 was immunohistochemically assessed in tumor specimens obtained from 778 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic parameters.ResultsThere was a relationship between p27Kip1status and benefit of cisplatin-based chemotherapy (test for interaction, P = .02). Among patients with p27Kip1-negative tumors, cisplatin-based chemotherapy resulted in longer overall survival compared with controls (adjusted hazard ratio [HR] for death = 0.66; 95% CI, 0.50 to 0.88; P = .006). In patients with p27Kip1-positive tumors, overall survival was not different between patients treated with cisplatin-based chemotherapy and controls (adjusted HR for death = 1.09; 95% CI, 0.82 to 1.45; P = .54). The other cell cycle regulators and Ki-67 did not predict benefit of adjuvant cisplatin-based chemotherapy. None of these biomarkers was significantly associated with overall survival of the patients in the total study population.ConclusionNSCLC patients with p27Kip1-negative tumors benefit from adjuvant cisplatin-based chemotherapy after complete tumor resection. Before establishing p27Kip1as a routine marker for selection of patients for adjuvant chemotherapy, the predictive value of p27Kip1has to be confirmed in patients from other trials.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/38316
Statistics
Document views: 24 File downloads: